Limited high-throughput screening compatibility of the phenuivirus cap-binding domain

Area of Science:

• Virology
• Drug Discovery
• Molecular Biology

Background:

• Bunyaviruses, including Rift Valley fever virus, are significant emerging pathogens with limited medical countermeasures.
• The cap-snatching mechanism is vital for bunyavirus replication, involving cap-binding and endonuclease activities.
• These activities are druggable targets, as seen in influenza viruses.

Purpose of the Study:

• To evaluate the phenuivirus cap-binding domain (CBD) as a drug target for antiviral strategies.
• To assess the suitability of the CBD for medium- and high-throughput drug discovery.

Main Methods:

• Development of in vitro assays to detect interactions between the CBD and m7GTP.
• Characterization of the CBD's binding pocket and affinity for cap analogs.

Main Results:

• The phenuivirus CBD possesses a shallow binding pocket.
• The CBD exhibits low affinity for its natural cap-ligand, m7GTP.
• These properties limit the CBD's potential as a target for small molecule drugs.

Conclusions:

• The phenuivirus cap-binding domain has limited potential for small molecule drug targeting via classical in vitro approaches.
• Further research may be needed to explore alternative strategies or targets within the cap-snatching machinery.